Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

25.12.24 15:45 Uhr

Werte in diesem Artikel
Aktien

341,80 EUR -5,10 EUR -1,47%

Indizes

19.310,8 PKT -176,0 PKT -0,90%

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.The Style Scores are broken down into four categories:Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.That's where the Style Scores come in.To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: United Therapeutics (UTHR) Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.UTHR is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.Additionally, the company could be a top pick for growth investors. UTHR has a Growth Style Score of B, forecasting year-over-year earnings growth of 27.3% for the current fiscal year.Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.49 to $25.22 per share. UTHR boasts an average earnings surprise of 4.2%.With a solid Zacks Rank and top-tier Growth and VGM Style Scores, UTHR should be on investors' short list.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Therapeutics Corporation (UTHR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf United Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf United Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu United Therapeutics Corp.

Analysen zu United Therapeutics Corp.

DatumRatingAnalyst
12.10.2018United Therapeutics BuyStandpoint Research
22.02.2018United Therapeutics UnderweightBarclays Capital
27.12.2017United Therapeutics OutperformWedbush Morgan Securities Inc.
27.04.2017United Therapeutics OutperformWedbush Morgan Securities Inc.
30.03.2017United Therapeutics SellUBS AG
DatumRatingAnalyst
12.10.2018United Therapeutics BuyStandpoint Research
27.12.2017United Therapeutics OutperformWedbush Morgan Securities Inc.
27.04.2017United Therapeutics OutperformWedbush Morgan Securities Inc.
28.03.2016United Therapeutics OutperformWedbush Morgan Securities Inc.
02.03.2016United Therapeutics OutperformWedbush Morgan Securities Inc.
DatumRatingAnalyst
19.01.2017United Therapeutics HoldStandpoint Research
15.06.2016United Therapeutics NeutralH.C. Wainwright & Co.
11.04.2016United Therapeutics Sector PerformRBC Capital Markets
29.07.2015United Therapeutics Sector PerformRBC Capital Markets
29.04.2015United Therapeutics Sector PerformRBC Capital Markets
DatumRatingAnalyst
22.02.2018United Therapeutics UnderweightBarclays Capital
30.03.2017United Therapeutics SellUBS AG
12.08.2008United Therapeutics ErsteinschätzungPiper Jaffray & Co.
03.05.2006United Therapeutics ausgestopptDer Aktionär

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für United Therapeutics Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"